InsidersTradesSigma
Delcath Systems, INC. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Delcath Systems, INC. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Delcath Systems, INC. has published 32 insider filings. Market capitalisation: €382.2m. The latest transaction was disclosed on 13 June 2025 (Levée d'options). Among the most active insiders: SALAMON STEVEN A J. The full history is openly available.
32
Insider Decl.
0
Thresholds
€6m
28 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Delcath Systems, INC. Strong Buy (bullish), based on 6 analysts. Average price target: US$21.29.
55Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 16,184 of 26,127 companies
44.5
score / 100
Value34
Quality55
FCF yld·
Earn yld0.6%
EV/EBITDA·
ROE0.6%
Gross mgn86%
Net mgn3.2%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 13 June 2025
Declarations32 total
42,000 shares@ US$4.78Common StockSEC:0001415889-25-017260:0
3,300 shares@ US$4.610.0038% mcap15.6% of flowCommon StockSEC:0000899243-22-018540:0
Ideal exit: 10 Feb 2023 (T+270)
5,000 shares@ US$5.0270.0063% mcap5.8% of flowCommon SharesSEC:0001019056-22-000388:0
Ideal exit: 7 Feb 2023 (T+270)
6,000 shares@ US$4.9040.0074% mcap6.8% of flowCommon SharesSEC:0001019056-22-000384:0
Ideal exit: 6 Feb 2023 (T+270)
1,600 shares@ US$6.250.0024% mcap0.1% of flowCommon SharesSEC:0001019056-22-000358:0
Ideal exit: 14 Jan 2023 (T+270)
1,600 shares@ US$6.250.0024% mcap2.2% of flowCommon SharesSEC:0001019056-22-000356:0
Ideal exit: 14 Jan 2023 (T+270)
2,000 shares@ US$6.34870.0031% mcap0.1% of flowCommon SharesSEC:0001019056-22-000354:0
Ideal exit: 13 Jan 2023 (T+270)
2,000 shares@ US$6.34870.0031% mcap100.0% of flowCommon SharesSEC:0001019056-22-000352:0
Ideal exit: 13 Jan 2023 (T+270)
200 shares@ US$6.340.0003% mcap0.2% of flowCommon StockSEC:0000899243-22-015014:0
Ideal exit: 13 Jan 2023 (T+270)
1,500 shares@ US$6.450.0023% mcap0.1% of flowCommon SharesSEC:0001019056-22-000344:0
Ideal exit: 8 Jan 2023 (T+270)
1,500 shares@ US$6.450.0023% mcap2.1% of flowCommon SharesSEC:0001019056-22-000340:0
Ideal exit: 8 Jan 2023 (T+270)
2,500 shares@ US$6.480.0039% mcap0.1% of flowCommon SharesSEC:0001019056-22-000334:0
Ideal exit: 7 Jan 2023 (T+270)
2,500 shares@ US$6.480.0039% mcap3.6% of flowCommon SharesSEC:0001019056-22-000332:0
Ideal exit: 7 Jan 2023 (T+270)
5,000 shares@ US$6.590.0079% mcap32.5% of flowCommon StockSEC:0000899243-22-014435:0
Ideal exit: 6 Jan 2023 (T+270)
1,000 shares@ US$6.490.0016% mcap0.1% of flowCommon SharesSEC:0001019056-22-000322:0
Ideal exit: 1 Jan 2023 (T+270)
1,000 shares@ US$6.490.0016% mcap1.4% of flowCommon SharesSEC:0001019056-22-000325:0
Ideal exit: 1 Jan 2023 (T+270)
1,000 shares@ US$6.590.0016% mcap1.2% of flowCommon StockSEC:0000899243-22-014377:0
Ideal exit: 3 Jan 2023 (T+270)
1,600 shares@ US$12.680.0045% mcap18.4% of flowCommon StockSEC:0000899243-22-013801:0
Ideal exit: 16 Aug 2021 (T+270)
2,000 shares@ US$7.560.0035% mcap0.1% of flowCommon SharesSEC:0001019056-22-000012:0
Ideal exit: 26 Sept 2022 (T+270)
2,000 shares@ US$7.560.0035% mcap3.2% of flowCommon SharesSEC:0001019056-22-000014:0
Ideal exit: 26 Sept 2022 (T+270)
23,200 shares@ US$8.610.046% mcap36.3% of flowCommon StockSEC:0000899243-21-046986:0
Ideal exit: 29 Aug 2022 (T+270)
5,500 shares@ US$12.760.015% mcap0.6% of flowCommon SharesSEC:0001019056-21-000395:0
Ideal exit: 27 Mar 2022 (T+270)
5,000 shares@ US$11.560.013% mcap0.5% of flowCommon SharesSEC:0001019056-21-000393:0
Ideal exit: 25 Mar 2022 (T+270)
5,500 shares@ US$12.760.015% mcap14.2% of flowCommon SharesSEC:0001019056-21-000397:0
Ideal exit: 27 Mar 2022 (T+270)
500,000 shares@ US$11.561.27% mcap48.5% of flowCommon SharesSEC:0001019056-21-000389:0
Ideal exit: 25 Mar 2022 (T+270)
25 of 32 declarations
About Delcath Systems, INC.
Delcath Systems, Inc. is a U.S.-based oncology-focused healthcare company listed on the Nasdaq Capital Market under the ticker DCTH, in the United States. Founded in 1988, the company was built around a highly specialized mission: developing liver-directed drug delivery systems designed to deliver high-dose chemotherapy to the liver while reducing systemic exposure. Its operating headquarters are in Queensbury, New York, giving Delcath the profile of a U.S. healthcare small cap with a strong clinical and regulatory overlay. ([investors.delcath.com](https://investors.delcath.com/ir-resources/faqs?utm_source=openai)) Delcath’s business is centered on two commercial platforms. In the U.S., the flagship product is HEPZATO KIT, a drug/device combination product used in the treatment of primary and metastatic liver cancers, especially where disease is liver-dominant. In Europe, the company markets CHEMOSAT, the device-based version of its hepatic delivery system, which is used at specialized medical centers for liver cancer treatment. This creates a business model that combines specialty pharma, medical devices, and clinical center activation and support. ([delcath.com](https://delcath.com/about-us/?utm_source=openai)) From a competitive standpoint, Delcath occupies a narrow but differentiated niche. It is not a broad diversified pharma group; instead, it is a focused interventional oncology player addressing a specific clinical need: regional hepatic chemotherapy delivery. That focus can be an advantage because it creates clear therapeutic positioning and a potentially defensible technology platform, but it also means the business is highly dependent on physician adoption, reimbursement, regulatory execution, and the pace of center activation. The FDA approval of HEPZATO and the establishment of a product-specific reimbursement code are important commercial milestones that support adoption and monetization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/872912/000162828026022951/dcth202510kforproxy.pdf?utm_source=openai)) Recent developments point to meaningful momentum. In 2025, Delcath reported strong revenue growth driven primarily by HEPZATO KIT, along with improving gross margins and an expanding treatment-center footprint. The company also advanced its clinical franchise: CHOPIN data were published in The Lancet Oncology in 2026, adding external validation to the platform’s clinical rationale. For investors, Delcath remains a specialized U.S. Nasdaq healthcare name with high operating leverage, where the key watch items are reimbursement durability, commercial uptake, clinical expansion, and continued execution in the U.S. and Europe. ([investors.delcath.com](https://investors.delcath.com/news-releases/news-release-details/delcath-systems-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
